A Dose-Escalation Study Of The Safety, Tolerability, And Pharmacokinetics Of Cabazitaxel In Combination With Cisplatin Administered Every 3 Weeks In Subjects With Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2014
At a glance
- Drugs Cabazitaxel (Primary) ; Cisplatin
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Sanofi
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Feb 2013 Planned End Date changed from 1 Dec 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 20 Aug 2012 Planned end date changed from 1 Oct 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.